Psoriasis Clinical Trial Pipeline: 80+ Companies Shaping the Future of Treatment

Leading pharmaceutical companies are driving innovation in the psoriasis treatment pipeline, unlocking new growth opportunities for the future of care.

DelveInsight's 'Psoriasis Pipeline Insight 2024' report provides comprehensive global coverage of pipeline Psoriasis therapies in various stages of clinical development. Major pharmaceutical companies are working to advance the pipeline space and future growth potential of the Psoriasis pipeline domain.

For Psoriasis emerging drugs, the Psoriasis pipeline analysis report provides a 360° view of the therapeutics landscape by development point, product type, route of administration, molecule type, and MOA. The pipeline research covers business opportunities, challenges, future partnerships, strong competitors, and growth strategies.

Key Takeaways from the Psoriasis Pipeline Report
• DelveInsight's Psoriasis Pipeline analysis depicts a robust space with 80+ active players working to develop 80+ pipeline drugs for Psoriasis treatment.
• The leading Psoriasis companies include Soligenix, Artax Biopharma Inc, Huabo Biopharm Co., Ltd., SFA Therapeutics, Taizhou Mabtech Pharmaceutical Co., Ltd., Bristol-Myers Squibb, Arctic Bioscience, Hansoh BioMedical R&D Company, Beijing InnoCare Pharma Tech Co., Ltd., Boehringer Ingelheim, Amgen, Janssen-Cilag International NV, Livzon Pharmaceutical Group Inc., Janssen Research & Development, LLC, Ganzhou Hemay Pharmaceutical Co., Ltd., Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd., BioRay Pharmaceutical Co., Ltd., Takeda, Janssen Pharmaceutical K.K., Can-Fite BioPharma, Abbvie, Novartis, AstraZeneca, Bausch Health, Eli Lilly, Sun Pharmaceutical, UCB Inc., LEO Pharma, Promius Pharma, Mayne Pharma, MC2 Therapeutics, Allergan, Dermavant Sciences, Pfizer, Arcutis Biotherapeutics, Merck, Arbor Pharmaceuticals, Dr. Reddy's Laboratories, Kadmon Pharmaceuticals, Affibody AB, Jiangsu HengRui Medicine, Santalis Pharmaceuticals, Astellas Pharma, Genentech, Mylan, Biocad, Celltrion, Coherus BioSciences, Iltoo Pharma, GlaxoSmithKline, Galectin Therapeutics, Evelo Biosciences, Galderma, BioMimetix JV, Menlo Therapeutics Inc., Aristea Therapeutics, UNION Therapeutics, MetrioPharm, Sienna Biopharmaceuticals, and others are evaluating their lead assets to improve the Psoriasis treatment landscape.
• Key Psoriasis pipeline therapies in various stages of development include Topical roflumilast, GSK2982772, Hypericin, AX-158, HB0017 Q4W, SFA002, CMAB015, BMS-986165, HRO350, HS-10374, ICP-488, BI 765250, Apremilast, Guselkumab, LZM012, Guselkumab, Hemay005, TQH3906, Guselkumab, TQH2929, BR201, TAK-279, JNJ-77242113, piclidenoson, and others.
• In December 2024, Celltrion announced that its biosimilar Ustekinumab-stba (Steqeyma) received FDA approval for subcutaneous injection or intravenous infusion. It is approved for the treatment of adult and pediatric patients with plaque psoriasis, arthritis, and psoriatic arthritis, as well as adult patients with Crohn's disease and ulcerative colitis.
• On October 14, 2024, Dong-A-ST announced that its Imuldosa (ustekinumab-srlf/DMB-3115), a biosimilar to Stelara, received FDA approval for the treatment of autoimmune diseases such as plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis. Stelara, a blockbuster drug developed by Janssen Biotech, generated $10.86 billion in sales globally in 2023, and Imuldosa's approval as a biosimilar offers a more cost-effective alternative for patients requiring long-term therapy for autoimmune conditions.

Request a sample and discover the recent breakthroughs happening in the Psoriasis pipeline landscape @ https://www.delveinsight.com/report-store/psoriasis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Psoriasis Overview
Psoriasis is a chronic inflammatory skin disorder driven by a combination of genetic, environmental, and immune system factors. This non-contagious dermatological condition affects approximately 2% of the global population, with its severity varying among individuals. The extent of skin involvement can range from mild (10%). Among its different forms, chronic plaque psoriasis (psoriasis vulgaris) is the most prevalent. The disease is characterized by an immune response involving dendritic cells, T lymphocytes, macrophages, neutrophils, and keratinocytes, which contribute to the formation of skin lesions. For individuals with mild to moderate psoriasis, topical therapies remain the primary treatment approach.

Find out more about Psoriasis medication @ https://www.delveinsight.com/report-store/psoriasis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Psoriasis Treatment Analysis: Drug Profile
Topical Roflumilast: Arcutis Biotherapeutics
Topical roflumilast cream (ARQ-151) is a small-molecule inhibitor targeting phosphodiesterase type 4 (PDE4), an intracellular enzyme that plays a key role in inflammation by promoting pro-inflammatory mediators while reducing anti-inflammatory signals. PDE4 has been implicated in several inflammatory conditions, including psoriasis, eczema, and chronic obstructive pulmonary disease (COPD). Currently, roflumilast is in Phase III clinical development for the treatment of plaque psoriasis.

GSK2982772: GlaxoSmithKline
GSK2982772 is a selective ATP-competitive inhibitor of receptor-interacting protein-1 (RIP1) kinase (RIPK1), with an IC50 value of 16 nM. By specifically targeting RIP1, the molecule effectively blocks numerous TNF-dependent cellular responses. RIP1 is recognized as a key upstream kinase involved in regulating inflammation through both scaffolding and kinase-specific mechanisms. GSK2982772 is currently in Phase I clinical development for the treatment of psoriasis.

Key Psoriasis Therapies and Companies
• Topical roflumilast: Arcutis Biotherapeutics
• GSK2982772: GlaxoSmithKline
• Hypericin: Soligenix,
• AX-158: Artax Biopharma Inc,
• HB0017 Q4W: Huabo Biopharm Co., Ltd.,
• SFA002: SFA Therapeutics,
• CMAB015: Taizhou Mabtech Pharmaceutical Co., Ltd.,
• BMS-986165: Bristol-Myers Squibb,
• HRO350: Arctic Bioscience,
• HS-10374: Hansoh BioMedical R&D Company,
• ICP-488: Beijing InnoCare Pharma Tech Co., Ltd.,
• BI 765250: Boehringer Ingelheim,
• Apremilast: Amgen,
• Guselkumab: Janssen-Cilag International NV,
• LZM012: Livzon Pharmaceutical Group Inc.,
• Guselkumab: Janssen Research & Development, LLC,
• Hemay005: Ganzhou Hemay Pharmaceutical Co., Ltd.,
• TQH3906: Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.,
• Guselkumab: Janssen Research & Development, LLC,
• TQH2929: Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.,
• BR201: BioRay Pharmaceutical Co., Ltd.,
• TAK-279: Takeda,
• JNJ-77242113: Janssen Pharmaceutical K.K.,
• piclidenoson: Can-Fite BioPharma.

Learn more about the novel and emerging Psoriasis pipeline therapies @ https://www.delveinsight.com/report-store/psoriasis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Psoriasis Therapeutics Assessment
By Product Type
• Mono
• Combination
• Mono/Combination.

By Stage
• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

By Route of Administration
• Oral
• Parenteral
• Intravitreal
• Subretinal
• Topical.
• Molecule Type

By Molecule Type
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Scope of the Psoriasis Pipeline Report
• Coverage: Global
• Key Psoriasis Companies: Alcon, Seikagaku Corporation, Huons, Aramis Biosciences, Invirsa, Inc., IVIEW Therapeutics, Seinda Pharmaceutical, Serentrix, EyeD Pharma, SELAGINE, Theratome Bio, Alchemedicine, Palatin Technologies, Inc., Aldeyra Therapeutics, Inc., ReGenTree/RegeneRx Biopharmaceuticals, Inc., Mimetogen, Alcon/Aerie Pharmaceuticals, BRIM Biotechnology, Inc., Mitotech, Senju Pharmaceutical, Sylentis, S.A./PharmaMar, Stuart Therapeutics, VivaVision Biotech, HanAll BioPharma Co., Ltd./Daewoong Pharmaceutical Co. Ltd., Redwood Pharma AB, AxeroVision, Inc., OKYO Pharma, Glaukos Corporation, Oculis, and others
• Key Psoriasis Pipeline Therapies: PL9643, Reproxalap, RGN-259 (Tß4), Tavilermide (MIM-D3), AR-15512, BRM421, SI-614, SkQ1 eye drops, SJP-0132, Tivanisiran (SYL1001), ST-100 (Vezocolmitide), VVN001, Tanfanercept Ophthalmic Solution/HL036, RP101, AXR-270 (cream), OK-101, AXR-270, AXR-159, GLK-301 (Pilocarpine Ophthalmic Topical Cream), Licaminlimab (OCS-02), and others.

Dive deep into rich insights for drugs used for Psoriasis treatment; visit @ https://www.delveinsight.com/report-store/psoriasis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Table of Contents
1. Introduction
2. Executive Summary
3. Psoriasis Pipeline: Overview
4. Analytical Perspective In-depth Commercial Assessment
5. Psoriasis Pipeline Therapeutics
6. Psoriasis Pipeline: Late-Stage Products (Phase III)
7. Psoriasis Pipeline: Late-Stage Products (Phase III)
8. Psoriasis Pipeline: Mid-Stage Products (Phase II)
9. Psoriasis Pipeline: Early Stage Products (Phase I)
10. Therapeutic Assessment
11. Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Key Companies
14. Key Products
15. Unmet Needs
16. Market Drivers and Barriers
17. Future Perspectives and Conclusion
18. Analyst Views
19. Appendix

Contact Us:
Jatin Vimal
jvimal@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

This release was published on openPR.